Roche and Egypt's UPA sign MoU on sustainable healthcare procurement
The collaboration is aimed at supporting the UPA in embedding green procurement principles and sustainability frameworks across all phases of its healthcare procurement lifecycle, from planning and acquisition to waste management. The initiative is aligned with Egypt's Vision 2030 for Sustainable Development and its national goals for environmental stewardship and resource-efficient healthcare.
Under the terms of the agreement, Roche Diagnostics will provide strategic consultancy to support the UPA in embedding environmental sustainability across its procurement policies and operations. The partnership will include tailored capacity-building programmes, such as experience exchange initiatives and hands-on workshops, to equip UPA teams and other stakeholders with practical tools and global expertise.
Both parties will also co-develop a comprehensive procurement guideline, aligned with international practices, to facilitate environmentally responsible decision-making throughout the healthcare supply chain.
Dr. Liliane Kanaan, General Manager of Roche Diagnostics in Egypt and North Africa, commented: 'At Roche, we believe that a sustainable healthcare system is an imperative. This collaboration with UPA showcases our shared commitment to building resilient, environmentally responsible supply chains. Together, we are taking bold steps to create tangible impact by reducing the healthcare sector's environmental footprint, as well as shaping a procurement model that balances progress with planetary responsibility.'
The agreement comes as environmental sustainability becomes a greater priority in policy-making and procurement for governments and international organisations, which are increasingly recognising that responsible sourcing can reduce costs and improve health outcomes.
Environmentally conscious procurement can reduce harmful emissions, waste, and the use of hazardous materials, contributing to a cleaner ecosystem and fewer health risks from environmental degradation. It can also generate long-term cost efficiencies through more energy-efficient operations and streamlined supply chains, while enhancing the resilience of healthcare supply networks and encouraging innovation in eco-friendly materials and greener manufacturing practices.
The partnership is consistent with Roche's global sustainability strategy, which integrates environmental, social, and economic priorities across its operations. The company has committed to achieving real zero greenhouse gas emissions by 2050 and embeds sustainability into its procurement by working with suppliers to reduce emissions and improve supply chain transparency.
Roche stated that most of its total carbon emissions are linked to its supply network, leading it to invest in initiatives such as the Sustainability Supplier Engagement Programme, the Sustainable Markets Initiative (SMI), and the Pharmaceutical Supply Chain Initiative (PSCI). These platforms are designed to help Roche and its partners collectively raise industry standards.
The MoU will allow the UPA to access Roche's participation in these global platforms, utilising international expertise and tested frameworks to support Egypt's sustainability agenda. By drawing on Roche's global networks, the collaboration positions Egypt to adopt procurement strategies that balance public health priorities with environmental stewardship, reinforcing Roche Diagnostics' role as a partner in developing Egypt's healthcare system.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily News Egypt
20-07-2025
- Daily News Egypt
Roche helps Egypt expand digital pathology and AI diagnostics
Roche Diagnostics is supporting Egypt's expansion of digital pathology and the integration of artificial intelligence into its public health system to improve the speed and accuracy of diagnoses, particularly in underserved regions, a company official said. The initiatives are being rolled out in partnership with the Ministry of Health and the Universal Health Insurance (UHI) system, according to Liliane Kanaan, North Africa Lead and General Manager for Egypt at Roche Diagnostics. Egypt is one of the first countries in Africa to adopt digital pathology at scale. The technology digitises tissue samples, allowing them to be viewed and analysed remotely. 'By reducing diagnostic turnaround times and enabling telepathology, this innovation will improve both the speed and equity of care delivery,' Kanaan said. 'In underserved communities, digital pathology will facilitate timely first opinions, helping patients receive a diagnosis locally without the need for extensive travel.' For more complex cases, the system allows for rapid second opinions from national or international experts. 'This significantly decreases the travel time and physical burden on both patients and healthcare professionals, while also accelerating diagnosis and treatment planning,' Kanaan added. Roche is also collaborating with national stakeholders to integrate AI into diagnostic workflows by deploying digital pathology scanners and AI-powered tools to modernise hospital pathology laboratories. Kanaan said this helps reduce the burden on healthcare professionals and directly addresses a critical skills gap. 'Notably, this solution directly addresses the severe shortage of pathologists across Africa, where statistics reveal there is approximately one pathologist for every one million people—compared to a ratio of about 1 to 25,000 in countries like the United States and United Kingdom,' she said. The company, which has operated in Egypt for over two decades, has been involved in several national health programmes. Kanaan cited collaborations that have contributed to national health outcomes, including Egypt's Hepatitis C elimination campaign. 'Roche played a key role in deploying national screening efforts, contributing to Egypt's recognition as a WHO Golden Tier country for HCV elimination—an achievement that reflects both the scale and effectiveness of the programme,' she stated. Other past partnerships include supporting the national blood safety strategy with Nucleic Acid Testing (NAT) technology at the National Blood Transfusion Center and providing over two million tests during the early stages of the COVID-19 pandemic. The company continues to support the Presidential Breast Cancer Initiative, launched in 2019, which has screened more than 30 million women to date. Aligning with national priorities like the Presidential Women's Health Initiative ensures innovation addresses the population's most pressing needs, Kanaan said. As part of this, Roche supported the upgrade of more than 26 public pathology laboratories across Egypt. 'These 26 upgraded sites enabled us to deliver over 20,000 full breast cancer diagnostic panels, an essential step in defining effective treatment plans for patients,' she said. Roche is also participating in the national cervical cancer early detection campaign, which has screened more than 20,000 women in collaboration with the Ministry of Health and several non-governmental organisations (NGOs). To meet the region's specific needs, Kanaan said the company localises its solutions by engaging with stakeholders including the Ministry of Health, UHI, military hospitals, academic institutions and NGOs. This involves providing comprehensive solutions that go beyond product sales to include capacity-building programmes, lab software and health consultancy services tailored to local infrastructure and regulations.
Mid East Info
10-07-2025
- Mid East Info
PharmaJet® Enters into MOU Agreement with Egyptian UPA and EVA Pharma to provide Needle-Free Delivery for Routine Immunization in Egypt
PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Memorandum of Understanding (MOU) agreement with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, to explore the integration of needle-free delivery of inactivated polio vaccine into Egypt's routine immunization program. The signing event took place in Cairo at the African Health ExCon healthcare conference on June 26. The agreement includes provisions for distribution, technology transfer, manufacturing, and new pharmaceutical product development, as well as collaborating to increase needle-free access within Egypt and regionally. The UPA seeks to incorporate new technologies into its portfolio, aiming to expand the benefits of vaccination against certain infectious agents, improve pandemic preparedness, reduce total immunization costs, and improve foreign exchange rates. Tropis® Needle-free adoption offers several strategic advantages for Egypt including substantial immunization cost savings of 38% or more over six years1, reduced vaccine hesitancy2,3, increased coverage2, and the potential for medical technology localization. EVA Pharma is a leading pharmaceuticals and medical appliances manufacturing company that has vast experience in manufacturing, registering, marketing, and promoting pharmaceutical products. 'This collaboration can transform immunization by making it safer, more accessible, and less painful for children and caregivers,' said Nicolas Boege, Director of Global Commercial & Corporate Development at EVA Pharma. 'By introducing this technology, alongside localized technology transfer and manufacturing, EVA Pharma is committed to scaling innovation that strengthens public health systems. We are proud to collaborate with UPA and PharmaJet to localize needle-free delivery and accelerate its integration into Egypt's immunization programs and beyond.' The adoption and introduction of Tropis with concurrent manufacturing technology transfer has the potential to advance UPA's goal of becoming the leader of immunization excellence and a hub of needle-free product manufacturing for the Middle East and Northern Africa. The current initiative will enhance pandemic preparedness, reduce immunization costs, and support Egypt's Universal Health Insurance project. It also emphasizes the critical importance of the first 1,000 days in a child's life, building on the earlier efforts of the '1000 Golden Days' presidential initiative. 'This collaboration with UPA and EVA Pharma has the potential to enable the children of Egypt to gain from the benefits of intradermal (ID) delivery with reduced pain and administration time. The UPA would benefit through cost savings and novel pharma product development and manufacturing opportunities with needle-free delivery, and we would be thrilled to expand PharmaJet's commercial applications into Egypt and regionally. It's a win-win all around,' said Paul LaBarre, Vice President of Business Development for PharmaJet. 'We look forward to contributing to early childhood development in this region by increasing the positive impact of needle-free immunization.' Tropis ID has been widely used for inactivated polio vaccine delivery in campaigns and supplemental immunization activities. It has been rigorously evaluated in a routine immunization setting in two recently published studies that showed greater than 94% acceptability amongst healthcare workers and caregivers3, reduced administration time3, and greater than 50% reduction in immunization adverse events compared with intradermal delivery with a needle.
Daily News Egypt
28-06-2025
- Daily News Egypt
Roche and Egypt's UPA sign MoU on sustainable healthcare procurement
Roche Diagnostics Egypt has signed a Memorandum of Understanding (MoU) with the Egyptian Authority for Unified Procurement (UPA) to help integrate environmental sustainability into the country's healthcare procurement system. The collaboration is aimed at supporting the UPA in embedding green procurement principles and sustainability frameworks across all phases of its healthcare procurement lifecycle, from planning and acquisition to waste management. The initiative is aligned with Egypt's Vision 2030 for Sustainable Development and its national goals for environmental stewardship and resource-efficient healthcare. Under the terms of the agreement, Roche Diagnostics will provide strategic consultancy to support the UPA in embedding environmental sustainability across its procurement policies and operations. The partnership will include tailored capacity-building programmes, such as experience exchange initiatives and hands-on workshops, to equip UPA teams and other stakeholders with practical tools and global expertise. Both parties will also co-develop a comprehensive procurement guideline, aligned with international practices, to facilitate environmentally responsible decision-making throughout the healthcare supply chain. Dr. Liliane Kanaan, General Manager of Roche Diagnostics in Egypt and North Africa, commented: 'At Roche, we believe that a sustainable healthcare system is an imperative. This collaboration with UPA showcases our shared commitment to building resilient, environmentally responsible supply chains. Together, we are taking bold steps to create tangible impact by reducing the healthcare sector's environmental footprint, as well as shaping a procurement model that balances progress with planetary responsibility.' The agreement comes as environmental sustainability becomes a greater priority in policy-making and procurement for governments and international organisations, which are increasingly recognising that responsible sourcing can reduce costs and improve health outcomes. Environmentally conscious procurement can reduce harmful emissions, waste, and the use of hazardous materials, contributing to a cleaner ecosystem and fewer health risks from environmental degradation. It can also generate long-term cost efficiencies through more energy-efficient operations and streamlined supply chains, while enhancing the resilience of healthcare supply networks and encouraging innovation in eco-friendly materials and greener manufacturing practices. The partnership is consistent with Roche's global sustainability strategy, which integrates environmental, social, and economic priorities across its operations. The company has committed to achieving real zero greenhouse gas emissions by 2050 and embeds sustainability into its procurement by working with suppliers to reduce emissions and improve supply chain transparency. Roche stated that most of its total carbon emissions are linked to its supply network, leading it to invest in initiatives such as the Sustainability Supplier Engagement Programme, the Sustainable Markets Initiative (SMI), and the Pharmaceutical Supply Chain Initiative (PSCI). These platforms are designed to help Roche and its partners collectively raise industry standards. The MoU will allow the UPA to access Roche's participation in these global platforms, utilising international expertise and tested frameworks to support Egypt's sustainability agenda. By drawing on Roche's global networks, the collaboration positions Egypt to adopt procurement strategies that balance public health priorities with environmental stewardship, reinforcing Roche Diagnostics' role as a partner in developing Egypt's healthcare system.
